Xulili

• Original drug research and development

• Discovery and confirmation of drug target

• Development of new analytical methods related to drug control

1、Educational Experience

2014/09-2017/07, China Pharmaceutical University, Pharmaceutical Engineering, PhD

2012/09-2014/07, China Pharmaceutical University, Pharmaceutical Engineering, Master

2、Working Experience

2021/07-present, School of Pharmacy, China Pharmaceutical University, Associate Professor

2020/09-2021/06, School of Pharmacy, China Pharmaceutical University, Lecturer

2017/09-2020/07, School of Pharmacy, China Pharmaceutical University, Postdoctoral

[1] Dai, Z.^#; An, L. Y. ^#; Chen, X. Y. ^#; et al; You, Q. D.^*; Di, B.^*; Xu, L. L.^* Target fishing reveals a novel mechanism of 1,2,4-oxadiazole derivatives targeting to Rpn6, a subunit of 26S Proteasome, Journal of Medicinal Chemistry, 2022, 65, 5029−5043. (SCI, IF = 8.039)

[2] Wang Y. H. ^#; Zhou M. Z. ^#; Ye Ta; Wang P. P.; Lu R.; Wang Y. L.; Liu C. X.; Xiao W.; Li J. Y.; Meng Z. B.; Xu L. L. ^*; Hu Q. H. ^*; and Jiang C.^* Discovery of a Series of 5-Amide-1H-pyrazole-3-carboxyl Derivatives as Potent P2Y₁₄R Antagonists with Anti-Inflammatory Characters. Journal of Medicinal Chemistry, 2022, 65, 23, 15967–15990. (SCI, IF = 8.039)

[3] Dai, Z.; Chen, X. Y.; An, L. Y.; Li, C. C.; Zhao, N.; Yang, F.; You, S. T.; Hou, C. Z.; Li, K.; Jiang, C.^*; You, Q. D.^*; Di, B.^*; Xu, L. L.^*, Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse, Journal of Medicinal Chemistry, 2021, 64, 871-889. (SCI, IF = 8.039)

[4] Li, C. C.; Zhao, N.; An, L. Y.; Dai, Z.; Chen, X. Y.; Yang, F.; You, Q. D.; Di, B.^*; Hu, C.^*; Xu, L. L.^*, Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRAS^G12C, Acta Pharmaceutica Sinica B, 2021, 11(9), 2670e2684. (SCI, IF = 14.907) 

[5] Zhao, N.; Di, B.^*; Xu, L. L.^*, The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine and Growth Factor Reviews, 2021, 61, 2–15. (SCI, IF = 17.660)

[6] Zhao, N.; Li, C. C.; Di, B.^*; Xu, L. L.^*, Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors, Journal of Autoimmunity, 2020, 113, 102515. (SCI, IF = 14.511)

[7] Cheng, S.; Shen, H.; Zhao, S.; Zhang, Y.; Xu, H.; Wang, L.; Di, B.^*; Xu, L. L.^*; Hu, C.^*, Orally administered mesoporous silica capped with the cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota, Nanoscale, 2020, 12(28), 15348-15363. (SCI, IF = 8.307)

[8] Xu, L. L.; Li, C. C.; An, L. Y.; Dai, Z.; Chen, X. Y.; You, Q. D.^*; Hu, C.^*; Di, B.^*, Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with D-amino acids in H358 cancer cells expressing KRAS^G12C, European Journal of Medicinal Chemistry, 2020, 185, 111844. (SCI, IF = 7.088) 

[9] Jia, J.; Wen, H.; Zhao, S.; Wang, L.; Qiao, H.; Shen, H.; Yu, Z.; Di, B.^*; Xu, L. L.^*; Hu, C.^*, Displacement Induced Off-On Fluorescent Biosensor Targeting IDO1 Activity in Live Cells, Analytical Chemistry, 2019, 91 (23), 14943-14950. (SCI, IF = 8.008) 

[10]Xu, L. L.; Wu, Y. F.; Yan, F.; Li, C. C.; Dai, Z.; You, Q. D.^*; Jiang, Z. Y.^*; Di, B.^*, 5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress, Free Radical Biology and Medicine, 2019,134, 288-303. (SCI, IF = 8.101)

[1] National Natural Science Foundation of China, General Program, Screening, design and synthesis of novel inhibitors that interfere with the formation of NEK7-NLRP3 inflammasome complexes and their application in the treatment of acute and chronic inflammation-related diseases (82173675), 2022.01~2025.12，RMB 550,000, host, ongoing..

[2] National Natural Science Foundation of China, Youth Program, Discovery, design, synthesis and exploration of NLRP3 inflammasome-targeted inhibitors for the treatment of non-controllable inflammatory disorders (81803354). 2019.01~2021.12，RMB 210,000, principal investigator, completed.

[3] Natural Science Foundation of Jiangsu Province, Youth Program, Design and synthesis of NLRP3-targeted inhibitors based on skeleton reconstruction strategy, and exploration of their therapeutic effects on non-controllable inflammatory disorders (BK20180564). 2018.07~2021.06，RMB 200,000, principal investigator, completed.

[4] China Postdoctoral Science Foundation, General Program, Discovery, optimization, activity evaluation, and mechanistic studies of ULK1 inhibitors (2017M620232), 2018.01~2021.01，RMB 80,000, principal investigator, completed.

[5] Fundamental Research Funds for the Central Universities, Key Program, Discovery and validation of novel oxadiazole-based anti-inflammatory target proteins using proteomics and molecular probe technology, 2021.01~2022.12, RMB 150,000, principal investigator, ongoing.

[6] National Natural Science Foundation of China, General Program, Discovery of ubiquitin E3 ligase Cbl-b inhibitors based on substrate-binding crucial features and exploration of their application in tumor immunotherapy (82173680), 2022.01 ~ 2025.12, RMB 550,000, ongoing, participating.

[7] National Natural Science Foundation of China, General Program, Discovery of targeted inducers of tau protein degradation conjugates based on ubiquitin E3 ligase Keap1 and exploration of their therapeutic application in Alzheimer's disease (81773581), 2018.01~2021.12, RMB 620,000, completed, participating.

[8] National Natural Science Foundation of China, Youth Program, Research on the application of GNN-based Raman hotspot regulation method in drug-target interaction (81803485), 2019.01 ~ 2021.12, RMB 210,000, completed, participating.

[9] Institutional commissioned project: Detection of drugs in urban wastewater in Jiangyin City, commissioned by the Jiangyin Public Security Bureau, RMB 69,100, principal investigator, ongoing.

[10] Industry commissioned project: Joint laboratory for drug detection between China Pharmaceutical University and Jiangsu Kangda Detection Technology Co., Ltd. (co-build laboratory), RMB 200,000, principal investigator, ongoing.

1. In 2021, Shimadzu Young Scholar Award, Rank first.

2. In 2022, Gold medal of the 5th International Patent Invention Exhibition in The Republic of North Macedonia (INOVAMAK 2022), Rank first.